Trump made Intel an offer it couldn’t refuse
Trump made Intel an offer it couldn’t refuse Summary On 25 August 2025 the US government purchased roughly 10% of Intel (about 433 million shares) for $8.9bn in a deal…
Trump made Intel an offer it couldn’t refuse Summary On 25 August 2025 the US government purchased roughly 10% of Intel (about 433 million shares) for $8.9bn in a deal…
Trump threatens extra tariffs, tech export bans, for any nation that dares to regulate Big Tech Summary US president Donald Trump used Truth Social to threaten ‘substantial additional Tariffs’ and…
Intel warned that converting $8.87 billion of CHIPS Act subsidies into an approximate 10% equity stake for the US government (at $20.74 per share) creates “unprecedented complications” and possible “adverse…
Two scrubs, one Starship: Third time lucky for SpaceX? Summary Elon Musk’s huge Starship stayed on the pad after two consecutive launch scrubs this weekend. The first abort came during…
AMD Blames Motherboard Makers For Burnt-Out CPUs Summary AMD’s X3D-series Ryzen processors — prized by gamers for extra L3 cache — have shown a small but troubling pattern of failures…
Apple Accuses Former Apple Watch Staffer of Conspiring to Steal Trade Secrets for Oppo Summary Apple has filed a lawsuit alleging that a former Apple Watch sensor systems architect, Dr…
Biotechs Turn to Digital Coins, Crypto to Boost Stock Prices Summary Small biotech firms, struggling with stalled funding and weak drug pipelines, are pivoting into cryptocurrencies — buying Ether, Litecoin…
Summary A University of Michigan team used a cradle-to-grave life cycle assessment (GREET model / Argonne data) to compare carbon emissions across vehicle types and locations in the US. They…
With a New Soyuz Rocket, Russia Seeks to Break Its Ukrainian Dependency Summary Russia plans to debut the Soyuz-5 rocket in December with a series of demonstration flights, according to…
AbbVie Targets Psychedelic-Based Depression Drug Market With $1.2 Billion Deal Summary AbbVie has agreed to acquire an experimental depression drug from Gilgamesh Pharmaceuticals for up to $1.2 billion, moving the…